Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Freegold Intersects 2.72 g/t Au over 139.9 metres at Golden Summit (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Agile Therapeutics Equity Warrants AGXRW

Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. Its product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Its initial product, Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system... see more

Recent & Breaking News (GREY:AGXRW)

Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L.

GlobeNewswire August 26, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALLG, DM, AGRX on Behalf of Shareholders

PR Newswire July 3, 2024

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Agile Therapeutics, Inc. - AGRX

PR Newswire July 3, 2024

Lifshitz Law PLLC Announces Investigations of AGRX, GRDI, INFN, and SPR

Accesswire July 1, 2024

AGILE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Agile Therapeutics, Inc. - AGRX

Business Wire June 28, 2024

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Agile Therapeutics, Inc. Buyout

Newsfile June 27, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AAN, TBNK, AGRX, UMBF on Behalf of Shareholders

PR Newswire June 26, 2024

AGRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Agile Therapeutics, Inc. Is Fair to Shareholders

Business Wire June 26, 2024

Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.

GlobeNewswire June 26, 2024

Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire May 15, 2024

Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire March 28, 2024

Agile Therapeutics Announces Delisting from Nasdaq

GlobeNewswire March 25, 2024

Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024

GlobeNewswire March 21, 2024

Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024

GlobeNewswire March 20, 2024

Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution

GlobeNewswire March 13, 2024

Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds

GlobeNewswire February 22, 2024

Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders' Equity Continued Listing Requirement & Provides Performance Update

GlobeNewswire February 15, 2024

The Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without Cost

GlobeNewswire January 23, 2024

Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act's No-Cost Contraceptive Coverage Requirement

GlobeNewswire December 12, 2023

Agile Therapeutics Posts Growth In Third Quarter Results, Reiterates Confidence In Target of $25M Net Revenue, Positive Cash Flow In 2024

Accesswire November 22, 2023